Friday, December 19, 2025
HomeNews

News

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous...

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced that the Italian Medicines Agency, or Agenzia Italiana del...

Use of BioMAP Platform to Assess Nutraceuticals Published in BioMed Central

Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, announces a...

Novavax COVID-19 Vaccine Nuvaxovid Recommended for Expanded Conditional Marketing Authorization

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has...

RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting that its U.S. joint venture (JV) partner...
0FansLike
0FollowersFollow
spot_img

Hot Topics